Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.

Abstract: An embodiment of the invention relates to method for increasing HDL-C in a patient in need thereof. An embodiment of the invention relates to a method for decreasing high blood pressure. An embodiment relates to a treatment method for a patient with refractory type 2 diabetes to provide normal HbA1C glycemia.

Abstract: A first subject of the present invention has an antiviral formulation with metallic copper particles in an unoxidized form and having a median particle diameter inferior or equal to 200 nm, graphene oxide or reduced graphene oxide, and a bonding matrix material. A second subject of the invention has an antiviral filtering material with a layer of textile and at least one layer of an antiviral coating comprising metallic copper particles in an unoxidized form and having a median particle diameter inferior or equal to 200 nm, graphene oxide or reduced graphene oxide, and a bonding matrix into which both metallic copper particles and graphene oxide or reduced graphene oxide are anchored. The invention also concerns methods of preparation of the antiviral formulation and of the antiviral filtering material. Finally, the invention includes an antiviral face mask with a layer of textile coated with the antiviral formulation.

Abstract: An organometallic compound represented by Formula 1: wherein M1 and M2 are each independently a first row transition metal, a second row transition metal, or a third row transition metal in the Periodic Table of Elements; and wherein L1, L2, a1, a2, Ar1, Ar2, R1 to R4, and LK in Formula 1 are as described in the present disclosure.

Abstract: The present invention relates to a solution for the preservation of cells from placental blood, from bone marrow and from peripheral blood.

Abstract: A method and a system for identifying the quality of a liquid pharmaceutical product as described. The method comprises providing a liquid pharmaceutical product in a sealed container and arranging the sealed container such that the liquid pharmaceutical product forms a sample layer in a first portion of the sealed container. The method further comprises directing a light beam through the sample layer and measuring a spectrum of the sample layer. The spectrum is chosen from the group of a NIR spectrum or a Raman spectrum. The method further comprises identifying the quality of the liquid pharmaceutical product by comparing the spectrum with a reference spectrum corresponding to an expected pharmaceutical product.

Abstract: An organometallic compound represented by Formula 1 wherein, M1 to M4 are each independently a first-row transition metal, a second-row transition metal, or a third-row transition metal; X1 and X2 are each independently C(R5)(R6), Si(R5)(R6), N(R5), O, S, Se, or Te; W1 to W4 are each independently N(R7)(R8), P(R7)(R8), S(R7), a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a; L1 to L6 are each independently a C1-C30 alkylene group unsubstituted or substituted with at least one R10a, a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a3 to a6 are each independently an integer from 0 to 3, and R1 to R8 and R10a in Formula 1 are as described herein.

Abstract: Scalable visualization of a containerized application in a multiple-cluster environment is disclosed. Deployment information that identifies a deployment status on a plurality of clusters of a set of resources that compose a containerized application is obtained. User interface imagery that identifies the set of resources, wherein each resource in the set is represented in the user interface imagery by only one corresponding resource representation, irrespective of a number of clusters on which the resource is deployed, is generated. A corresponding group deployment status indicator based on a deployment status of the resource on each cluster on which the resource was to be deployed is determined for at least one resource. The corresponding group deployment status indicator is included in association with the resource representation that corresponds to the resource. The user interface imagery is presented on a display device.

Abstract: An organometallic compound represented by Formula 1: wherein M1 and M2 are each independently a Period 1 transition metal, a Period 2 transition metal, or a Period 3 transition metal in the periodic table of elements; and wherein L1, L2, a1, a2, Ar1, Ar2, R1 to R4, and LK in Formula 1 are as described in the present disclosure.

Abstract: A method of regulating at least one cellular process in one or more cells by exposing the one or more cells to ultrasound, characterised in that the method comprises either (a) introducing into the one or more cells a construct comprising a regulatory transgene capable of regulating the at least one cellular process operably linked to a light-inducible control sequence and (b) inducing the expression of the regulatory transgene using sonoluminescence (SL) or sonochemiluminescence (SCL); or (i) contacting the one or more cells with one or more light-sensitive proteins capable of regulating the at least one cellular process and (ii) regulating the function of the one or more proteins using sonoluminescence or sonochemiluminescence.

Abstract: The present invention relates to a solution for the preservation of cells from placental blood, from bone marrow and from peripheral blood

Abstract: An apparatus for separately storing recyclable and/or disposable refuse in separate inner containers within one outer receptacle. Two nestable and duplicate interior recycle can inserts are used to separate the refuse. One interior recycle can insert may store the recyclable refuse and the second interior recycle can insert may store the disposable refuse until they are ready for emptying. Each interior recycle can insert tapers from the top periphery to the lower periphery to facilitate easy insertion and removal from the outer receptacle. Each interior recycle can insert has air holes to equalize relative air pressure such that the interior recycle can inserts may be easily removable from the outer receptacle. Each interior recycle can insert has cut-out handle and a contoured handle surface to allow easy insert to the outer receptacle and easy removal from the outer receptacle. The device replaces conventional trash cans and is useful for recycling.